Study record
β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease
Ikonomidis I, Katogiannis K, Kyriakou E et al. · J Thromb Thrombolysis · 2020
Human obs.Endogenous MOTS-c measuredEvidence tier B
What this study reported
In adults with type 2 diabetes and coronary artery disease, low MOTS-c, high β-amyloid and high on-clopidogrel platelet reactivity were each predictors of cardiac death and acute coronary syndromes over 2 years of follow-up after adjustment. Patients with high platelet reactivity and low MOTS-c had about fourfold higher risk; results were reported as confirmed in an external validation cohort.
Limitations
Observational design with a modest number of events; MOTS-c threshold derived within the study.
Study record
| Study model | Human observational |
|---|---|
| Substance studied | Endogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given. |
| Species | human |
| System studied | Patients with type 2 diabetes and revascularized coronary artery disease on clopidogrel and aspirin |
| Population | adults with type 2 diabetes and recently revascularized coronary artery disease |
| Design | Prospective cohort with external validation cohort |
| Sample size as reported | 121 patients (93 males) plus an external validation cohort of 90 |
| Control group | Not reported |
| Route (data field only) | Not reported |
| Endpoints measured | platelet reactivity (LTAmax); blood MOTS-c; β-amyloid; malondialdehyde; MACE over 2 years of follow-up |
| Pathways measured | Oxidative stress |
| Research areas | Cardiovascular · Metabolic |
| Evidence tier | B — Other human study |
| Publication types | Clinical Trial, Journal Article, Multicenter Study |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Human
- Sample size
- Adequate
- Controls
- n/a
- Outcome validity
- Clinical outcome
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.